Piramal Pharma Reduces Emissions by 22.6%, Increases Renewable Energy Use to 41%
Piramal Pharma Limited has achieved a 22.6% reduction in Scope 1 and 2 emissions, marking a company milestone. The company also reported an increase in renewable energy usage to 41%.
MUMBAI, India – Piramal Pharma Limited has reported significant environmental performance improvements, including a 22.6% decrease in Scope 1 and 2 emissions, reaching the lowest-ever levels for the company. Concurrently, the pharmaceutical firm increased its use of renewable energy to 41%.
These achievements are part of Piramal Pharma's commitment to its Science Based Targets initiative (SBTi) decarbonisation plan. The company aims to reduce its environmental footprint across its global operations.
In addition to its environmental progress, Piramal Pharma also reported zero OAI observations from the U.S. Food and Drug Administration (USFDA), highlighting adherence to stringent quality and regulatory standards. The company is a global pharmaceutical entity listed on the Indian stock exchanges (NSE: PPLPHARMA | BSE: 543635).
The reported emissions reduction and increased reliance on renewable energy underscore the company's strategic focus on sustainable operations. Piramal Pharma continues to invest in developing and implementing sustainable practices throughout its business.